Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China

OBJECTIVE: We aimed to evaluate the cost-effectiveness of camrelizumab plus chemotherapy compared with chemotherapy alone as the first-line treatment for patients with metastatic or advanced non-squamous non-small cell lung cancer (NSCLC) without targetable epidermal growth factor receptor or anapla...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Hongbin, Wang, Wenyue, Fan, Xin, Chen, Yongfa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971596/
https://www.ncbi.nlm.nih.gov/pubmed/36865055
http://dx.doi.org/10.3389/fmed.2023.1122731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9971596/
https://www.ncbi.nlm.nih.gov/pubmed/36865055
http://dx.doi.org/10.3389/fmed.2023.1122731

Ejemplares similares